Brazikumab (MEDI2070 , initially known as AMG139) is a key therapeutic candidate targeting interleukin-17F . New investigational findings from the ongoing NYMPH3 trial evaluating its benefit in individuals with moderate to severe psoriatic arthritis have revealed mixed findings. While preliminary